Correlation Between Premium Income and Rakovina Therapeutics
Can any of the company-specific risk be diversified away by investing in both Premium Income and Rakovina Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Premium Income and Rakovina Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Premium Income and Rakovina Therapeutics, you can compare the effects of market volatilities on Premium Income and Rakovina Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Premium Income with a short position of Rakovina Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Premium Income and Rakovina Therapeutics.
Diversification Opportunities for Premium Income and Rakovina Therapeutics
0.32 | Correlation Coefficient |
Weak diversification
The 3 months correlation between Premium and Rakovina is 0.32. Overlapping area represents the amount of risk that can be diversified away by holding Premium Income and Rakovina Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Rakovina Therapeutics and Premium Income is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Premium Income are associated (or correlated) with Rakovina Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Rakovina Therapeutics has no effect on the direction of Premium Income i.e., Premium Income and Rakovina Therapeutics go up and down completely randomly.
Pair Corralation between Premium Income and Rakovina Therapeutics
Assuming the 90 days trading horizon Premium Income is expected to under-perform the Rakovina Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Premium Income is 3.17 times less risky than Rakovina Therapeutics. The stock trades about -0.02 of its potential returns per unit of risk. The Rakovina Therapeutics is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest 16.00 in Rakovina Therapeutics on September 12, 2024 and sell it today you would lose (2.00) from holding Rakovina Therapeutics or give up 12.5% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Premium Income vs. Rakovina Therapeutics
Performance |
| Timeline |
| Premium Income |
| Rakovina Therapeutics |
Premium Income and Rakovina Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Premium Income and Rakovina Therapeutics
The main advantage of trading using opposite Premium Income and Rakovina Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Premium Income position performs unexpectedly, Rakovina Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rakovina Therapeutics will offset losses from the drop in Rakovina Therapeutics' long position.| Premium Income vs. Sprott Physical Gold | Premium Income vs. Brompton Split Banc | Premium Income vs. TDb Split Corp | Premium Income vs. Prime Dividend Corp |
| Rakovina Therapeutics vs. Premium Income | Rakovina Therapeutics vs. E L Financial Corp | Rakovina Therapeutics vs. Fairfax Financial Holdings | Rakovina Therapeutics vs. Fairfax Fin Hld |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Complementary Tools
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |